Randox Cardiac Array detects MI in six hours

This array simultaneously and quantitatively tests four cardiac biomarkers using a single patient sample, reliable within the critical three to six hour post pain-onset treatment window.

The Randox Cardiac Array combines the gold standard troponin test with CK-MB, myoglobin and heart fatty-acid binding protein (H-FABP).

H-FABP is used as an ischaemic indicator and as an early marker of cardiac muscle damage.

As a single marker, H-FABP is a powerful identifier of high-risk MI patients, independent of troponin.

As a multi-analyte test, the Cardiac Biochip Array provides even greater diagnostic performance, with 20 per cent increased sensitivity compared with testing troponin alone and a 98 per cent rule-out for MI within three to six hours of pain onset.

This means cardiac patients requiring intervention are prioritised and that non-MI patients can be quickly and effectively managed, freeing up hospital resources.

The Randox biochip array technology is based on familiar ELISA principles, with the cardiac array utilising sandwich chemiluminescent immunoassays.

Three biochip analysers are available; the Evidence, a fully automated, high-throughput analyser; the Investigator semi-automated medium-volume analyser; and the Multistat fully automated analyser.

The Multistat is an easy to use, near-patient biochip platform providing rapid laboratory-quality results in 20 minutes.

All Randox biochip analysers are suitable for a range of biochip arrays, providing a cost effective, multi-analyte solution to clinical and research needs.

Randox is also offering the Cardiac Plus expanded research array.

In addition to the four markers on the Cardiac biochip, Cardiac Plus contains Glycogen Phosphorylase BB and Carbonic Anhydrase III.

This combination is used in sports medicine, for example to allow elite athletes to monitor cardiac stress during and after endurance competitions.